Monday , December 18 2017
Home / KEEP BUT DO NOT DISPLAY / Facts / Novo Moving Once-Daily Oral Version of Semaglutide Into Phase 3 Trials

Novo Moving Once-Daily Oral Version of Semaglutide Into Phase 3 Trials

They decided to initiate a phase 3a program with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a program, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER program will include six safety and efficacy trials and one trial for evaluating the cardiovascular safety of oral semaglutide.